Curewell Capital

Curewell Capital is a Los Angeles-based private equity firm focused on growth-stage healthcare companies, partnering with entrepreneurs to scale tech-enabled care delivery platforms. The firm targets disruptive clinical and service businesses rather than early-stage software, and it does not list AI as a dedicated thesis. Limited public information is available on fund size, but the disclosed check size of $5M to $25M places it firmly in the lower-middle-market growth segment.

The firm operates from Los Angeles and writes equity checks in the $5M-$25M range, which typically corresponds to control-oriented or significant minority investments in companies with established revenue and unit economics. Stage focus is growth, meaning it is generally a Series C-or-later check for venture-backed founders, or a recapitalization for bootstrapped operators. Geographic deployment skews to U.S.-based care delivery businesses. No specific portfolio companies are listed in the source data.

Founders should approach Curewell only when they have meaningful clinical and financial traction, a defensible operating model, and a willingness to take on growth equity rather than dilutive seed capital. This is the wrong investor for an AI tool at the prototype, design partner, or early ARR stage. The right profile is a physician-founder running a tech-enabled services business that has cleared roughly $5M+ in revenue and needs scale capital.